PolyMedix Presents Data on Anti-Tuberculosis Activity of its Novel Antibiotic Compounds

New Directions In AIDS Treatment Research Policy and Care Symposium Held September 26, 2008, in New York City

<!-- start story body -->

RADNOR, Pa., Sept. 29, 2008--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, presented new data at the New Directions in AIDS Treatment Research Policy and Care Symposium in New York on September 26th, 2008. Pre-clinical in vitro data describing the activity of a variety of PolyMedixs novel small molecule defensin mimetic antibiotic compounds against Mycobacterium tuberculosis, the bacteria which causes tuberculosis, were presented.

PolyMedixs lead antibiotic product candidate, PMX-30063, with an initial planned indication to broadly treat Staph infections, is currently undergoing Phase I clinical testing.

About PolyMedix, Inc.

PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs and biomaterials for the treatment of infectious diseases and acute cardiovascular disorders. PolyMedixs compounds are based on biomimetics: non-peptide small molecule drugs and polymers that mimic the activity of proteins. The Companys antibiotic compounds, including PMX-30063 small molecule mimetics of human host-defense proteins - have a completely different mechanism of action from current antibiotic drugs, a mechanism which is intended to make bacterial resistance unlikely to develop. These compounds are being developed as rapidly acting antibiotics for serious systemic and local infections. The Company plans to continue the development of polymeric formulations as antimicrobial biomaterials, which can be used as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces. The Companys heptagonist compounds, including PMX-60056, reverse the activity of both heparin and Low Molecular Weight Heparins, with the goal of developing an antagonist drug that is safer and easier to use than currently approved therapy. PMX-30063 antibiotic and PMX-60056 heptagonist are currently undergoing clinical testing. For more information, please visit PolyMedix on its website at www.polymedix.com.

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and that could cause PolyMedixs actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. PolyMedix has in some cases identified forward-looking statements by using words such as anticipates, believes, hopes, estimates, looks, expects, plans, intends and similar expression. Among other things, there can be no assurance that PolyMedixs compounds will enter or successfully complete clinical testing or be granted regulatory approval to be sold and marketed in the Unites States or elsewhere. A more complete description of these risks, uncertainties and assumptions is included in PolyMedixs filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. PolyMedix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as may be required by applicable law or regulation.

 

<!-- end story body --><!-- end story -->
<!-- start contacts -->

Contacts

PolyMedix, Inc.
Lona Cornish, 484-598-2340
lcornish@polymedix.com
or
The Investor Relations Group
212-825-3210
Investors:
Erika Moran
emoran@investorrelationsgroup.com
or
Media:
Steven Melfi
smelfi@investorrelationsgroup.com

 

Posted: September 2008

View comments

Hide
(web4)